Related references
Note: Only part of the references are listed.Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343
Kayo Yukawa-Takamatsu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of a Gatekeeper Antagonist that Blocks Entry Pathway to Retinoid X Receptors (RXRs) without Allosteric Ligand Inhibition in Permissive RXR Heterodimers
Masaki Watanabe et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
New tools in MolProbity validation: CaBLAM for CryoEM backbone, UnDowser to rethink waters, and NGL Viewer to recapture online 3D graphics
Michael G. Prisant et al.
PROTEIN SCIENCE (2020)
A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats
Shuyue Ren et al.
PHARMACEUTICS (2020)
Comprehensive Set of Tertiary Complex Structures and Palmitic Acid Binding Provide Molecular Insights into Ligand Design for RXR Isoforms
Apirat Chaikuad et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Tuning Nuclear Receptor Selectivity of Wy14,643 towards Selective Retinoid X Receptor Modulation
Julius Pollinger et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Unique Polypharmacology Nuclear Receptor Modulator Blocks Inflammatory Signaling Pathways
Mi Ra Chang et al.
ACS CHEMICAL BIOLOGY (2019)
3H-Imidazo[4,5-b]pyridine-6-carboxylic acid derivatives as rexinoids with reduced teratogenicity
Yuta Takamura et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2019)
Alternative retinoid X receptor (RXR) ligands
Wojciech Krezel et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2019)
Therapeutic modulation of retinoid X receptors - SAR and therapeutic potential of RXR ligands and recent patents
Simone Schierle et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Discovery of the First in Vivo Active Inhibitors of the Soluble Epoxide Hydrolase Phosphatase Domain
Jan S. Kramer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
A Novel Biphenyl-based Chemotype of Retinoid X Receptor Ligands Enables Subtype and Heterodimer Preferences
Julius Pollinger et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Computer-Assisted Discovery and Structural Optimization of a Novel Retinoid X Receptor Agonist Chemotype
Pascal Heitel et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Nuclear receptors as potential drug targets in osteoarthritis
Margaret Man-Ger Sun et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Computer-Assisted Discovery of Retinoid X Receptor Modulating Natural Products and Isofunctional Mimetics
Daniel Merk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Morphology, in vivo distribution and antitumor activity of bexarotene nanocrystals in lung cancer
Yongjie Wang et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2017)
Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas
Toshihisa Hamada et al.
JOURNAL OF DERMATOLOGY (2017)
Nonacidic Farnesoid X Receptor Modulators
Daniel Flesch et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease
M. M. Mariani et al.
SCIENTIFIC REPORTS (2017)
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators
Pascal Heitel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE
Kevin P. Koster et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2017)
An Endogenous Mammalian Retinoid X Receptor Ligand, At Last!
Angel R. de Lera et al.
CHEMMEDCHEM (2016)
Preparation, in vitro and in vivo evaluation of bexarotene nanocrystals with surface modification by folate-chitosan conjugates
Li Li et al.
DRUG DELIVERY (2016)
One-pot preparation of 2,5-disubstituted and 2,4,5-trisubstituted oxazoles from aromatic ketones with molecular iodine, oxone, and trifluoromethanesulfonic acid in nitriles
Sho Imai et al.
TETRAHEDRON (2015)
NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
Jurema Schmidt et al.
SCIENTIFIC REPORTS (2015)
Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides
Alessandro Pileri et al.
IMMUNOTHERAPY (2013)
Therapeutic modulators of peroxisome proliferator-activated receptors (PPAR): a patent review (2008-present)
Christina Lamers et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2012)
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Paige E. Cramer et al.
SCIENCE (2012)
Structure, Energetics, and Dynamics of Binding Coactivator Peptide to the Human Retinoid X Receptor α Ligand Binding Domain Complex with 9-cis-Retinoic Acid
Gang Xia et al.
BIOCHEMISTRY (2011)
Regulation of remyelination in multiple sclerosis
Khalid A. Hanafy et al.
FEBS LETTERS (2011)
Retinoid X receptor gamma signaling accelerates CNS remyelination
Jeffrey K. Huang et al.
NATURE NEUROSCIENCE (2011)
Bexarotene Induces Dyslipidemia by Increased Very Low-Density Lipoprotein Production and Cholesteryl Ester Transfer Protein-Mediated Reduction of High-Density Lipoprotein
Jitske de Vries-van der Weij et al.
ENDOCRINOLOGY (2009)
Reduction of lipophilicity at the lipophilic domain of RXR agonists enables production of subtype preference:: RXRα-preferential agonist possessing a sulfonamide moiety
Kayo Takamatsu et al.
CHEMMEDCHEM (2008)
International Union of Pharmacology. LXIII. Retinoid X receptors
Pierre Germain et al.
PHARMACOLOGICAL REVIEWS (2006)
Carnosic acid and carnosol, phenolic diterpene compounds of the labiate herbs rosemary and sage, are activators of the human peroxisome proliferator-activated receptor gamma
Oliver Rau et al.
PLANTA MEDICA (2006)
Selective optimization of side activities: Another way for drug discovery
CG Wermuth
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Application of associative neural networks for prediction of lipophilicity in ALOGPS 2.1 program
IV Tetko et al.
JOURNAL OF CHEMICAL INFORMATION AND COMPUTER SCIENCES (2002)
Share Paper
